Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Rios · SciRah

Researcher profile · Semantic Scholar

M. Rios

Share profile

M. Rios — researcher profile on SciRah

h-index: 53
Works: 140
Citations: 9,025

Most-cited papers

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E. Jabbour, H. Kantarjian, Dan A. Jones, M. Talpaz +9 more
2006Leukemia407 citations Open access
Semantic Scholar
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
H. Kantarjian, D. Thomas, J. Jorgensen, E. Jabbour +14 more
2012The Lancet Oncology401 citations
Semantic Scholar
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero +9 more
2004Blood398 citations
Semantic Scholar
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
H. Kantarjian, S. O'Brien, E. Jabbour, G. Garcia-Manero +11 more
2011Blood331 citations Open access
Semantic Scholar
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
E. Jabbour, H. Kantarjian, Dan A. Jones, Jenny Shan +8 more
2009Blood318 citations Open access
Semantic Scholar
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
J. Cortes, M. Talpaz, S. O'Brien, Dan A. Jones +8 more
2005Clinical Cancer Research293 citations Open access
Semantic Scholar
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Patricia S. Ault, H. Kantarjian, S. O'Brien, S. Faderl +7 more
2006Journal of Clinical Oncology245 citations
Semantic Scholar
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
H. Kantarjian, M. Talpaz, S. O'Brien, Daniel Jones +7 more
2006Blood222 citations
Semantic Scholar
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Lin-Hua Jin, Y. Tabe, S. Konoplev, Yuan-Yuan Xu +9 more
2008Molecular Cancer Therapeutics212 citations Open access
Semantic Scholar
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α
H. Kantarjian, J. Cortes, S. O'Brien, R. Luthra +9 more
2004165 citations
Semantic Scholar
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
E. Jabbour, H. Kantarjian, S. O'Brien, Jenny Shan +6 more
2010Blood158 citations Open access
Semantic Scholar
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
E. Jabbour, H. Kantarjian, L. Abruzzo, S. O'Brien +5 more
2005Blood151 citations
Semantic Scholar
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
K. Chamoun, H. Kantarjian, Rami Atallah, G. Nogueras-González +13 more
2019Journal of Hematology & Oncology141 citations Open access
Semantic Scholar
Staging of chronic myeloid leukemia in the imatinib era
J. Cortes, M. Talpaz, S. O'Brien, S. Faderl +6 more
2006Cancer133 citations Open access
Semantic Scholar
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
Thomas B. Sneed, H. Kantarjian, M. Talpaz, S. O'Brien +8 more
2004Cancer131 citations Open access
Semantic Scholar
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
A. Quintás-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien +8 more
2005Blood124 citations
Semantic Scholar
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
Maha El-Zimaity, H. Kantarjian, M. Talpaz, S. O'Brien +11 more
2004British Journal of Haematology110 citations
Semantic Scholar
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Dushyant Verma, H. Kantarjian, S. Strom, M. Rios +6 more
2008Blood102 citations Open access
Semantic Scholar
Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure
H. Kantarjian, S. O'Brien, M. Talpaz, G. Borthakur +7 more
2007Cancer97 citations Open access
Semantic Scholar
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Ehab Atallah, J. Cortes, S. O'Brien, S. Pierce +6 more
2007Blood90 citations
Semantic Scholar
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
E. Jabbour, H. Kantarjian, S. O'Brien, J. Shan +4 more
2011Journal of Clinical Oncology81 citations Open access
Semantic Scholar
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
E. Jabbour, H. Kantarjian, S. O'Brien, M. Rios +4 more
2006Blood81 citations Open access
Semantic Scholar
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
E. Jabbour, H. Kantarjian, S. O'Brien, Jenny Shan +6 more
2011Blood79 citations Open access
Semantic Scholar
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
H. Kantarjian, J. Shan, Daniel Jones, S. O'Brien +3 more
2009Journal of Clinical Oncology74 citations Open access
Semantic Scholar
Survival benefit with imatinib mesylate therapy in patients with accelerated‐phase chronic myelogenous leukemia—Comparison with historic experience
H. Kantarjian, M. Talpaz, S. O'Brien, F. Giles +8 more
2005Cancer73 citations
Semantic Scholar
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
H. Kantarjian, J. Cortes, S. O'Brien, R. Luthra +9 more
2004Blood73 citations
Semantic Scholar
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
G. Issa, H. Kantarjian, G. Nogueras-González, G. Borthakur +14 more
2017Blood71 citations Open access
Semantic Scholar
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
Carlos E. Bueso-Ramos, J. Cortes, M. Talpaz, S. O'Brien +4 more
2004Cancer61 citations Open access
Semantic Scholar
Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
H. Kantarjian, S. O'Brien, J. Cortes, F. Giles +10 more
2004Clinical Cancer Research61 citations
Semantic Scholar
Granulocyte–colony‐stimulating factor (filgrastim) may overcome imatinib‐induced neutropenia in patients with chronic‐phase chronic myelogenous leukemia
A. Quintás-Cardama, H. Kantarjian, S. O'Brien, G. Garcia-Manero +3 more
2004Cancer58 citations
Semantic Scholar
Patient-driven discontinuation of tyrosine kinase inhibitors – single institution experience
O. Benjamini, H. Kantarjian, M. Rios, E. Jabbour +9 more
2013Leukemia and Lymphoma43 citations Open access
Semantic Scholar
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase
J. Cortes, S. O'Brien, A. Quintás, F. Giles +4 more
2004Cancer43 citations Open access
Semantic Scholar
Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia
J. Foran, F. Ravandi, S. O'Brien, G. Borthakur +7 more
200841 citations
Semantic Scholar
Incidence of Second Malignancies in Patients with Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors
K. Sasaki, H. Kantarjian, S. O'Brien, F. Ravandi +12 more
2019International journal of hematology33 citations Open access
Semantic Scholar
Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
Alexey V. Danilov, B. Fakhri, Farrukh T. Awan, H. Bentzen +19 more
2024Blood30 citations
Semantic Scholar
Prediction for Sustained Deep Molecular Response of BCR-ABL1 Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase
K. Sasaki, H. Kantarjian, S. O'Brien, F. Ravandi +12 more
2017Cancer30 citations Open access
Semantic Scholar
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
C. Fava, H. Kantarjian, E. Jabbour, S. O'Brien +8 more
2009Blood27 citations Open access
Semantic Scholar
Imatinib Front-Line Therapy Is Safe and Effective in Patients With Chronic Myelogenous Leukemia With Pre-Existing Liver and/or Renal Dysfunction
W. Tong, H. Kantarjian, S. O'Brien, S. Faderl +6 more
2010Cancer25 citations Open access
Semantic Scholar
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
K. Sasaki, E. Jabbour, F. Ravandi, M. Konopleva +17 more
2020American journal of hematology/oncology24 citations Open access
Semantic Scholar
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy
H. Kantarjian, C. Bueso-Ramos, M. Talpaz, S. O'Brien +4 more
2005Leukemia and Lymphoma23 citations
Semantic Scholar
Significance of myelofibrosis in early chronic‐phase, chronic myelogenous leukemia on imatinib mesylate therapy
H. Kantarjian, Carlos E. Bueso-Ramos, M. Talpaz, S. O'Brien +6 more
2005Cancer22 citations
Semantic Scholar
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Patricia S. Ault, H. Kantarjian, M. Welch, F. Giles +2 more
2004Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis21 citations
Semantic Scholar
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations
K. Naqvi, J. Cortes, R. Luthra, S. O'Brien +11 more
2018International journal of hematology16 citations
Semantic Scholar
A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib
A. Craig, H. Kantarjian, J. Cortes, D. Jones +7 more
200715 citations
Semantic Scholar
Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
Dan A. Jones, Su S. Chen, E. Jabbour, M. Rios +2 more
2010Blood13 citations Open access
Semantic Scholar
Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia.
M. Rios, Patricia S. Ault
2011Clinical Journal of Oncology Nursing12 citations
Semantic Scholar
Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.
Dushyant Verma, H. Kantarjian, Jenny Shan, S. O'Brien +6 more
200912 citations
Semantic Scholar
Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.
E. Jabbour, H. Kantarjian, S. O'Brien, Jenny Shan +6 more
200912 citations
Semantic Scholar
Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)
S. O'Brien, D. Thomas, M. Ohanian, J. Jorgensen +15 more
20117 citations
Semantic Scholar
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia
Isam A. Abdel-Karim, William K. Jr Plunkett, S. O'Brien, F. Giles +10 more
2010Investigational new drugs7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Kantarjian×44
Invite
H. Kantarjian — researcher profile on SciRah
S. O'Brien×42
Invite
S. O'Brien — researcher profile on SciRah
J. Cortes×40
Invite
J. Cortes — researcher profile on SciRah
G. Garcia-Manero×28
Invite
G. Garcia-Manero — researcher profile on SciRah

×23

Invite

E. Jabbour — researcher profile on SciRah

Invite

M. Talpaz — researcher profile on SciRah

Invite

F. Ravandi — researcher profile on SciRah

Invite

S. Faderl — researcher profile on SciRah

Invite

F. Giles — researcher profile on SciRah

S. Verstovsek×17

Invite

S. Verstovsek — researcher profile on SciRah

Invite

J. Shan — researcher profile on SciRah

G. Borthakur×14

Invite

G. Borthakur — researcher profile on SciRah